Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 233-238

  Schwaab, Juliana ^a   Knut, Marcin ^b   Haferlach, Claudia ^c   Metzgeroth, Georgia ^a   Horny, Hans Peter ^d   Chase, Andrew ^b,e   Tapper, William ^b   Score, Joannah ^b,e   Waghorn, Katherine ^b,e   Naumann, Nicole ^a   Jawhar, Mohamad ^a   Fabarius, Alice ^a   Hofmann, Wolf Karsten ^a   Cross, Nicholas C P ^b,e   Reiter, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

Author keywords

JAK2 fusion genes; Relapse; Remission; Ruxolitinib

Indexed keywords

LACTATE DEHYDROGENASE; RUXOLITINIB; TRANSCRIPTOME; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; JANUS KINASE; ONCOPROTEIN; PCM1-JAK2 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ARTICLE; BCR JAK2 FUSION GENE; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 18; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME PAINTING; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PCM1 JAK2 FUSION GENE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; THROMBOCYTE COUNT; TREATMENT RESPONSE; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REMISSION; TIME; TUMOR RECURRENCE;

AMINO ACID SEQUENCE; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCR; PYRAZOLES; REMISSION INDUCTION; TIME FACTORS;

EID: 84926627909     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2221-y     Document Type: Article

References (16)

1. Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168
2. Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807
3. Reiter A, Walz C, Watmore A et al (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65:2662–2667
4. Griesinger F, Hennig H, Hillmer F et al (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosome Cancer 44:329–333
5. Peeters P, Raynaud SD, Cools J et al (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90:2535–2540
6. Walz C, Cross NC, Van Etten RA et al (2008) Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22:1320–1334
7. Valent P, Gleich GJ, Reiter A et al (2012) Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 5:157–176
8. Chase A, Bryant C, Score J et al (2013) Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica 98:404–408
9. Lierman E, Selleslag D, Smits S et al (2012) Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 120:1529–1531
10. Rumi E, Milosevic JD, Casetti I et al (2013) Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol 31(17):e269–71
11. Langmead B, Trapnell C, Pop M et al (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10:R25
12. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25:1105–1111
13. Kim D, Salzberg SL (2011) TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 12:R72
14. Savage N, George TI, Gotlib J (2013) Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. Int J Lab Hematol 35(5):491–500
15. Metzgeroth G, Schwaab J, Gosenca D, et al. (2013) Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia
16. Jovanovic JV, Score J, Waghorn K et al (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109:4635–4640